XML 137 R67.htm IDEA: XBRL DOCUMENT v3.25.3
Sale of Future Revenue - Narrative (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended 12 Months Ended 59 Months Ended
Nov. 03, 2020
Sep. 30, 2025
Sep. 30, 2024
Jun. 30, 2020
Sep. 30, 2025
Sep. 30, 2024
Dec. 31, 2024
Sep. 30, 2025
Disaggregation of Revenue [Line Items]                
Payments for loan acquisition costs         $ 21 $ 18    
Revenues   $ 12,807 $ 13,542   31,530 $ 45,694    
Royalty                
Disaggregation of Revenue [Line Items]                
Revenues         $ 922   $ 1,008  
MAM Pangolin Royalty , LLC | Maximum                
Disaggregation of Revenue [Line Items]                
Proceeds from sale of future revenue $ 125,000              
License agreement with Sunovion Pharmaceuticals, Inc.                
Disaggregation of Revenue [Line Items]                
Minimum annual royalty receivable       $ 1,000        
License agreement with Sunovion Pharmaceuticals, Inc. | Royalty                
Disaggregation of Revenue [Line Items]                
Revenues       $ 8,000        
Monetization Agreement                
Disaggregation of Revenue [Line Items]                
Payments for loan acquisition costs $ 2,909              
Effective annual interest rate 24.90%              
Monetization Agreement | MAM Pangolin Royalty , LLC                
Disaggregation of Revenue [Line Items]                
Proceeds from sale of future revenue $ 40,000             $ 50,000
Additional proceeds from sale of future revenue 10,000              
Proceeds from debt, contingent on additional milestones $ 75,000